X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PANACEA BIOTECH - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PANACEA BIOTECH ASTRAZENECA PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 142.4 -20.5 - View Chart
P/BV x 21.6 2.9 750.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PANACEA BIOTECH
Mar-14
ASTRAZENECA PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,285149 864.2%   
Low Rs63482 770.4%   
Sales per share (Unadj.) Rs189.684.1 225.3%  
Earnings per share (Unadj.) Rs-0.2-18.3 1.1%  
Cash flow per share (Unadj.) Rs3.8-6.7 -57.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.683.7 82.0%  
Shares outstanding (eoy) m25.0061.25 40.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.4 368.7%   
Avg P/E ratio x-4,712.7-6.3 74,696.6%  
P/CF ratio (eoy) x249.6-17.2 -1,447.5%  
Price / Book Value ratio x14.01.4 1,013.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9887,074 339.1%   
No. of employees `0001.62.8 56.7%   
Total wages/salary Rs m1,6051,449 110.7%   
Avg. sales/employee Rs Th3,040.21,874.1 162.2%   
Avg. wages/employee Rs Th1,029.2527.0 195.3%   
Avg. net profit/employee Rs Th-3.3-407.7 0.8%   
INCOME DATA
Net Sales Rs m4,7405,154 92.0%  
Other income Rs m92100 92.3%   
Total revenues Rs m4,8325,254 92.0%   
Gross profit Rs m-130-766 16.9%  
Depreciation Rs m101711 14.2%   
Interest Rs m01,503 0.0%   
Profit before tax Rs m-139-2,881 4.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m1391,771 7.8%   
Tax Rs m517 30.3%   
Profit after tax Rs m-5-1,121 0.5%  
Gross profit margin %-2.7-14.9 18.4%  
Effective tax rate %-3.7-0.6 628.3%   
Net profit margin %-0.1-21.8 0.5%  
BALANCE SHEET DATA
Current assets Rs m2,7263,810 71.6%   
Current liabilities Rs m2,4358,365 29.1%   
Net working cap to sales %6.1-88.4 -7.0%  
Current ratio x1.10.5 245.8%  
Inventory Days Days74156 47.4%  
Debtors Days Days4167 60.6%  
Net fixed assets Rs m1,03514,480 7.1%   
Share capital Rs m5061 81.6%   
"Free" reserves Rs m942903 104.4%   
Net worth Rs m1,7165,127 33.5%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m4,15619,433 21.4%  
Interest coverage xNM-0.9-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.10.3 430.0%   
Return on assets %-0.12.0 -6.2%  
Return on equity %-0.3-21.9 1.4%  
Return on capital %03.6 0.0%  
Exports to sales %5.724.5 23.2%   
Imports to sales %6.510.2 63.5%   
Exports (fob) Rs m2701,264 21.4%   
Imports (cif) Rs m306525 58.4%   
Fx inflow Rs m3751,539 24.3%   
Fx outflow Rs m470942 49.9%   
Net fx Rs m-96597 -16.0%   
CASH FLOW
From Operations Rs m-8599 -1.4%  
From Investments Rs m-146-438 33.3%  
From Financial Activity Rs m862-303 -284.9%  
Net Cashflow Rs m709-141 -501.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.6 50.0%  
FIIs % 15.7 1.3 1,207.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.6 38.6%  
Shareholders   12,856 10,259 125.3%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 25, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS